Proteomics Scientist

Proxima (formerly VantAI) is discovering the next generation of proximity therapeutics by making protein interactions programmable. Our platform brings together frontier AI models, a scalable data generation engine, and a partnership track record exceeding $5B in collaborations across the world’s leading biopharma and tech organizations. We’ve recently closed an oversubscribed seed round with an elite group of VCs including DCVC, NVIDIA’s NVentures, AIX, Yosemite among others.

Neo is our all-atom foundation model that combines state-of-the-art structure prediction and molecular generation in a single system. Neo enables rapid exploration of chemical and structural space for high value, previously intractable targets, and in particular unlocks small molecule proximity therapeutics like molecular glues with AI for the first time.

In parallel, we are developing an advanced structural interactomics platform ( NeoLink ) built on proprietary proteomics technology and a lab equipped with next-generation mass spectrometry instrumentation. This platform produces proteome-scale maps of protein interactions and identifies small molecules that modulate proximity. Together with Neo, it creates an integrated system capable of co-folding protein complexes while generating candidate small molecules to influence those interactions. Proximity-based therapeutics represent one of most promising frontiers in modern drug discovery with the potential to treat previously intractable diseases and target ‘undruggable’ proteins. We’re building the tech and the team to make that happen. Come join us!